After a $6 billion tax hit, net income at Amgen fell 74 percent in 2017, coming off a fourth quarter in which revenues decreased 3 percent to $5.8 billion and net losses reached $4.26 billion. The Thousand Oaks-based biotech giant also announced that its board of directors increased its share repurchase program by $10 billion,…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
